Literature DB >> 8320172

Detection of active form of transforming growth factor-beta in cerebrospinal fluid of patients with glioma.

T Tada1, K Yabu, S Kobayashi.   

Abstract

We examined transforming growth factor-beta (TGF-beta) activity in cerebrospinal fluid of 39 patients with various brain tumors, and found it in 10 glioma cases that had lesions related to subarachnoid space or ventricle. In one glioma case, TGF-beta detected on admission disappeared after radiation and chemotherapy. We confirmed that five glioma cell lines produced TGF-beta, and that four of them produced active form of TGF-beta directly. The active form of TGF-beta was also identified from cerebrospinal fluid before the acidification treatment in two cases. The calculated contents were 110 ng/ml and 18 ng/ml. These results indicate that active form of TGF-beta is directly produced by tumor cells in patients with glioma, and may contribute to immunodeficiency of the host.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8320172      PMCID： PMC5919170          DOI： 10.1111/j.1349-7006.1993.tb00174.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN： 0910-5050


  14 in total

1.  Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state.

Authors:  T Tada; S Ohzeki; K Utsumi; H Takiuchi; M Muramatsu; X F Li; J Shimizu; H Fujiwara; T Hamaoka
Journal:  J Immunol       Date:  1991-02-01       Impact factor: 5.422

2.  Growth factors from murine sarcoma virus-transformed cells.

Authors:  J E de Larco; G J Todaro
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

3.  Latent transforming growth factor-beta in serum. A specific complex with alpha 2-macroglobulin.

Authors:  M D O'Connor-McCourt; L M Wakefield
Journal:  J Biol Chem       Date:  1987-10-15       Impact factor: 5.157

4.  The TGF-beta family of growth and differentiation factors.

Authors:  J Massagué
Journal:  Cell       Date:  1987-05-22       Impact factor: 41.582

5.  The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors.

Authors:  S Cheifetz; J A Weatherbee; M L Tsang; J K Anderson; J E Mole; R Lucas; J Massagué
Journal:  Cell       Date:  1987-02-13       Impact factor: 41.582

6.  New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues.

Authors:  A B Roberts; M A Anzano; L C Lamb; J M Smith; M B Sporn
Journal:  Proc Natl Acad Sci U S A       Date:  1981-09       Impact factor: 11.205

7.  Latent transforming growth factor-beta from human platelets. A high molecular weight complex containing precursor sequences.

Authors:  L M Wakefield; D M Smith; K C Flanders; M B Sporn
Journal:  J Biol Chem       Date:  1988-06-05       Impact factor: 5.157

8.  Transforming growth factor-beta: biological function and chemical structure.

Authors:  M B Sporn; A B Roberts; L M Wakefield; R K Assoian
Journal:  Science       Date:  1986-08-01       Impact factor: 47.728

9.  Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family.

Authors:  R de Martin; B Haendler; R Hofer-Warbinek; H Gaugitsch; M Wrann; H Schlüsener; J M Seifert; S Bodmer; A Fontana; E Hofer
Journal:  EMBO J       Date:  1987-12-01       Impact factor: 11.598

10.  Elevated levels of plasma transforming growth factor-beta in patients with hepatocellular carcinoma.

Authors:  Y Shirai; S Kawata; N Ito; S Tamura; K Takaishi; S Kiso; H Tsushima; Y Matsuzawa
Journal:  Jpn J Cancer Res       Date:  1992-07
View more
  8 in total

1.  Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models.

Authors:  Soon Young Park; Yuji Piao; Kang Jin Jeong; Jianwen Dong; John F de Groot
Journal:  Mol Cancer Ther       Date:  2016-06-15       Impact factor: 6.261

2.  Suppression of TGF-beta1 in human gliomas by retroviral gene transfection enhances susceptibility to LAK cells.

Authors:  R Yamanaka; R Tanaka; S Yoshida; T Saitoh; K Fujita; H Naganuma
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

3.  Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma.

Authors:  Thomas Schneider; Michael Sailer; Siegfried Ansorge; Raimund Firsching; Dirk Reinhold
Journal:  J Neurooncol       Date:  2006-04-14       Impact factor: 4.130

4.  Inflammation and Gliomagenesis: Bi-Directional Communication at Early and Late Stages of Tumor Progression.

Authors:  Rui Pedro Galvão; Hui Zong
Journal:  Curr Pathobiol Rep       Date:  2013-03-01

Review 5.  Challenges in clinical design of immunotherapy trials for malignant glioma.

Authors:  Cleo E Rolle; Sadhak Sengupta; Maciej S Lesniak
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

Review 6.  Cytokines: shifting the balance between glioma cells and tumor microenvironment after irradiation.

Authors:  Wei Zhou; Zheng Jiang; Xingang Li; Yangyang Xu; Zhenyu Shao
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-09       Impact factor: 4.553

Review 7.  Tumor invasion, proteolysis, and angiogenesis.

Authors:  U P Thorgeirsson; C K Lindsay; D W Cottam; D E Gomez
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

8.  Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines.

Authors:  M Weller; K Frei; P Groscurth; P H Krammer; Y Yonekawa; A Fontana
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.